Key Points
-
Histone deacetylases (HDACs) regulate gene expression and protein function by catalysing the removal of acetyl groups from the lysines of histone tails and a large number of signalling molecules and other non-histone proteins. Much effort has gone into development of HDAC inhibitors (HDACIs), especially for applications in oncology.
-
Accruing studies indicate that HDACI therapy might also be of use in non-oncology settings, including during inflammation and autoimmunity. Most of these studies have employed a one-size-fits-all approach and used pan-HDACIs. Pan-HDACI use can limit dendritic cell differentiation and curb dendritic cell and T cell activation, resulting in beneficial effects in experimental models of arthritis, inflammatory bowel disease and transplant rejection. Initial clinical trials, including some in Phase II, are also showing evidence of HDACI tolerability, safety and efficacy.
-
A subset of T lymphocytes expressing the transcription factor, FOXP3, are of increasing interest as these so-called regulatory T cells (Tregs) limit inflammation and autoimmunity in humans and experimental animals. Recently, FOXP3 itself was shown to be regulated by acetylation by histone acetyltransferases, and deacetylation by HDACs. Exposure to pan-HDACIs increases FOXP3+ Treg production, Foxp3 acetylation and Treg suppressive functions in vitro and in vivo.
-
Experimental studies indicate that a subset of HDAC proteins, especially of the class II family of HDACs, is of particular relevance to control of Treg functions. Several studies have pointed to the value of targeting HDAC7 and HDAC9 (class IIa HDAC) and also HDAC6 (class IIb). Development of selective pharmacological inhibitors of individual HDACs, or associated interacting proteins, may provide significant benefits compared with use of pan-HDACIs.
-
Ongoing analysis of HDAC structure–function relationships and the development of new and selective HDACIs have the promise of providing powerful new therapies for immuno-inflammatory disorders.
Abstract
Classical zinc-dependent histone deacetylases (HDACs) catalyse the removal of acetyl groups from histone tails and also from many non-histone proteins, including the transcription factor FOXP3, a key regulator of the development and function of regulatory T cells. Many HDAC inhibitors are in cancer clinical trials, but a subset of HDAC inhibitors has important anti-inflammatory or immunosuppressive effects that might be of therapeutic benefit in immuno-inflammatory disorders or post-transplantation. At least some of these effects result from the ability of HDAC inhibitors to enhance the production and suppressive functions of FOXP3+ regulatory T cells. Understanding which HDACs contribute to the regulation of the functions of regulatory T cells may further stimulate the development of new class- or subclass-specific HDAC inhibitors with applications beyond oncology.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19, 1176–1179 (2000).
Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev. Cancer 6, 38–51 (2006).
Sadoul, K., Boyault, C., Pabion, M. & Khochbin, S. Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie. 90, 306–312 (2008).
Spange, S., Wagner, T., Heinzel, T. & Kramer, O. H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 41, 185–198 (2009).
Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840 (2009). Eye-opening landmark paper illustrating the extent of acetylation of non-histone proteins.
Li, B. et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl Acad. Sci. USA 104, 4571–4576 (2007). Important study that highlighted the dynamic complexing of HATs and HDACs with FOXP3.
Tao, R. et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nature Med. 13, 1299–1307 (2007). This paper shows the potential for regulation of T reg function by modulation of FOXP3 acetylation in vitro and in vivo using HDACIs.
Yang, X. J. & Seto, E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nature Rev. Mol. Cell Biol. 9, 206–218 (2008). Superb overview of class I and class II HDAC structure and function.
Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature Rev. Genet. 10, 32–42 (2009). Latest of a fine series of reviews from this group highlighting the involvement of HDACs in diseases other than cancer.
Baur, J. A. & Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev. Drug Discov. 5, 493–506 (2006).
Lavu, S., Boss, O., Elliott, P. J. & Lambert, P. D. Sirtuins — novel therapeutic targets to treat age-associated diseases. Nature Rev. Drug Discov. 7, 841–853 (2008).
Zhang, J. et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J. Clin. Invest. 1 Sep 2009 (doi:10.1172/JCI38902).
Villagra, A. et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature Immunol. 10, 92–100 (2009).
Blanchard, F. & Chipoy, C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov. Today 10, 197–204 (2005).
Karagiannis, T. C. & El-Osta, A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 21, 61–65 (2007).
Adcock, I. M. HDAC inhibitors as anti-inflammatory agents. Br. J. Pharmacol. 150, 829–831 (2007).
Brunkow, M. E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature Genet. 27, 68–73 (2001).
Bennett, C. L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genet. 27, 20–21 (2001).
Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor FOXP3. Science 299, 1057–1061 (2003).
Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. FOXP3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunol. 4, 330–336 (2003).
Khattri, R., Cox, T., Yasayko, S. A. & Ramsdell, F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nature Immunol. 4, 337–342 (2003).
Chai, J. G. et al. In vitro expansion improves in vivo regulation by CD4+CD25+ regulatory T cells. J. Immunol. 180, 858–869 (2008).
Riley, J. L., June, C. H. & Blazar, B. R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30, 656–665 (2009). State-of-the art review of cellular therapy using human T regs.
Chen, C., Rowell, E. A., Thomas, R. M., Hancock, W. W. & Wells, A. D. Transcriptional regulation by FOXP3 is associated with direct promoter occupancy and modulation of histone acetylation. J. Biol. Chem. 281, 36828–36834 (2006). Important study that first noted the need for TCR-activation to drive FOXP3-associated chromatin remodelling and the upregulation, as well as the more recognized downregulation, of gene expression by T regs.
Samanta, A. et al. TGF-β and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc. Natl Acad. Sci. USA 105, 14023–14027 (2008).
de Zoeten, E. F., Wang, L., Sai, H. & Hancock, W. W. HDAC9 as a therapeutic target in murine colitis. Gastroenterology (in the press). Shows the importance of HDAC9 as a regulator of FOXP3-dependent functions, and the functionally significant physical association of FOXP3 with HSP70.
Reilly, C. M. et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun 31, 123–130 (2008).
Saouaf, S. J. et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87, 99–104 (2009).
McDonel, P., Costello, I. & Hendrich, B. Keeping things quiet: roles of NuRD and Sin3 co-repressor complexes during mammalian development. Int. J. Biochem. Cell Biol. 41, 108–116 (2009).
Grozinger, C. M., Hassig, C. A. & Schreiber, S. L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl Acad. Sci. USA 96, 4868–4873 (1999).
Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45–57 (2002).
Lahm, A. et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl Acad. Sci. USA 104, 17335–17340 (2007). Fascinating explanation of why class IIa HDACs lack significant HDAC activity.
Jones, P. et al. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med. Chem. Lett. 18, 1814–1819 (2008).
Lemercier, C. et al. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J. Biol. Chem. 277, 22045–22052 (2002).
Zhang, C. L., McKinsey, T. A., Lu, J. R. & Olson, E. N. Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor. J. Biol. Chem. 276, 35–39 (2001).
Zhang, C. L., McKinsey, T. A. & Olson, E. N. Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol. Cell Biol. 22, 7302–7312 (2002).
Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479–488 (2002).
Chang, S., Bezprozvannaya, S., Li, S. & Olson, E. N. An expression screen reveals modulators of class II histone deacetylase phosphorylation. Proc. Natl Acad. Sci. USA 102, 8120–8125 (2005).
Berdeaux, R. et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nature Med. 13, 597–603 (2007).
Grozinger, C. M. & Schreiber, S. L. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl Acad. Sci. USA 97, 7835–7840 (2000).
Han, A., He, J., Wu, Y., Liu, J. O. & Chen, L. Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. J. Mol. Biol. 345, 91–102 (2005).
McKinsey, T. A., Zhang, C. L. & Olson, E. N. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl Acad. Sci. USA 97, 14400–14405 (2000).
Angelelli, C. et al. Differentiation-dependent lysine 4 acetylation enhances MEF2C binding to DNA in skeletal muscle cells. Nucleic Acids Res. 36, 915–928 (2008).
Paroni, G. et al. PP2A regulates HDAC4 nuclear import. Mol. Biol. Cell 19, 655–667 (2008).
Wang, Z. et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138, 1019–1031 (2009). Major study showing the widespread regulation of gene expression by interacting HATs and HDACs.
Valenzuela-Fernandez, A., Cabrero, J. R., Serrador, J. M. & Sanchez-Madrid, F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 18, 291–297 (2008).
Richon, V. M. & O'Brien, J. P. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res. 8, 662–664 (2002).
Bottomley, M. J. et al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem. 283, 26694–26704 (2008).
Schuetz, A. et al. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 283, 11355–11363 (2008).
Somoza, J. R. et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12, 1325–1334 (2004).
Vannini, A. et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA 101, 15064–15069 (2004).
Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov. 5, 769–784 (2006).
Walkinshaw, D. R. & Yang, X. J. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr. Oncol. 15, 237–243 (2008).
Mai, A. & Altucci, L. Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol. 41, 199–213 (2009).
Gibson, P. R. The intracellular target of butyrate's actions: HDAC or HDON'T? Gut 46, 447–448 (2000).
Vezzani, A. & Granata, T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 46, 1724–1743 (2005).
Rasheed, W., Bishton, M., Johnstone, R. W. & Prince, H. M. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev. Anticancer Ther. 8, 413–432 (2008).
Lee, M. J., Kim, Y. S., Kummar, S., Giaccone, G. & Trepel, J. B. Histone deacetylase inhibitors in cancer therapy. Curr. Opin. Oncol. 20, 639–649 (2008).
Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Rev. Drug Discov. 1, 287–299 (2002).
Richon, V. M., Garcia-Vargas, J. & Hardwick, J. S. Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett. (2009).
Hu, E. et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307, 720–728 (2003).
Jones, P. et al. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem. 51, 2350–2353 (2008).
Massa, S. et al. 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J. Med. Chem. 44, 2069–2072 (2001).
Mai, A. et al. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem. 48, 3344–3353 (2005).
Muraglia, E. et al. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg Med. Chem. Lett. 18, 6083–6087 (2008).
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M. & Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100, 4389–4394 (2003). This paper presents the first evidence of a selective pharmacological inhibitor of a single HDAC isoform, HDAC6.
Balasubramanian, S. et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22, 1026–1034 (2008).
Kramer, O. H. et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22, 3411–3420 (2003). The first of various studies to highlight additional mechanisms of action of HDACIs than simply blocking HDAC catalytic activity.
Dokmanovic, M. et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol. Cancer Ther. 6, 2525–2534 (2007).
Scognamiglio, A. et al. HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim. Biophys. Acta 1783, 2030–2038 (2008).
Backs, J., Backs, T., Bezprozvannaya, S., McKinsey, T. A. & Olson, E. N. Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol. Cell Biol. 28, 3437–3445 (2008).
Shahbazian, M. D. & Grunstein, M. Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem. 76, 75–100 (2007).
Sobel, R. E., Cook, R. G., Perry, C. A., Annunziato, A. T. & Allis, C. D. Conservation of deposition-related acetylation sites in newly synthesized histones H3 and H4. Proc. Natl Acad. Sci. USA 92, 1237–1241 (1995).
Moreira, J. M., Scheipers, P. & Sorensen, P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 3, 30 (2003). Classic and comprehensive study of the effects of TsA on T cells.
Gregoretti, I. V., Lee, Y. M. & Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338, 17–31 (2004).
Chen, C. S., Weng, S. C., Tseng, P. H. & Lin, H. P. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280, 38879–38887 (2005).
Brogdon, J. L. et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109, 1123–1130 (2007).
Leoni, F. et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl Acad. Sci. USA 99, 2995–3000 (2002).
Backdahl, L., Bushell, A. & Beck, S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int. J. Biochem. Cell Biol. 41, 176–184 (2009).
Nencioni, A. et al. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer Res. 13, 3933–3941 (2007).
Bosisio, D. et al. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J. Leukoc. Biol. 84, 1540–1548 (2008).
Sun, Y. et al. Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J. Immunol. 182, 5899–5903 (2009).
Reddy, P. et al. Histone deacetylase inhibition modulates indoleamine 2, 3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118, 2562–2573 (2008).
Matsuoka, H. et al. Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem. Pharmacol. 74, 465–476 (2007).
Matsuoka, H., Fujimura, T., Mori, H., Aramori, I. & Mutoh, S. Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int. Immunopharmacol. 7, 1422–1432 (2007).
Edens, R. E., Dagtas, S. & Gilbert, K. M. Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 6, 1673–1681 (2006).
Huber, L. C. et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum. 56, 2755–2764 (2007).
Zhou, Q. et al. Histone deacetylase inhibitors blocked activation and caused senescence of corneal stromal cells. Mol. Vis. 14, 2556–2565 (2008).
Wang, Z. et al. SAHA- a potential epigenetic therapeutic agent for lung fibrosis? Eur. Respir. J. 12 Feb 2009 (doi:10.1183/09031936.00084808).
Yoshikawa, M., Hishikawa, K., Marumo, T. & Fujita, T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-β1 in human renal epithelial cells. J. Am. Soc. Nephrol. 18, 58–65 (2007).
Shan, B. et al. Requirement of HDAC6 for transforming growth factor-β1-induced epithelial-mesenchymal transition. J. Biol. Chem. 283, 21065–21073 (2008).
Glenisson, W., Castronovo, V. & Waltregny, D. Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation. Biochim. Biophys. Acta 1773, 1572–1582 (2007).
Choi, J. H. et al. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin. Exp. Allergy 35, 89–96 (2005).
Camelo, S. et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 164, 10–21 (2005).
Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P. & Gilkeson, G. S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111, 539–552 (2003).
Glauben, R. et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176, 5015–5022 (2006).
Nishida, K. et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 50, 3365–3376 (2004).
Lin, H. S. et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150, 862–872 (2007).
Reddy, P. et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA 101, 3921–3926 (2004).
Li, N. et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl Acad. Sci. USA 105, 4796–4801 (2008).
Granger, A. et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 22, 3549–3560 (2008).
Marumo, T., Hishikawa, K., Yoshikawa, M. & Fujita, T. Epigenetic regulation of BMP7 in the regenerative response to ischemia. J. Am. Soc. Nephrol. 19, 1311–1320 (2008).
Kim, H. J. et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321, 892–901 (2007).
Ryu, H. et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl Acad. Sci. USA 100, 4281–4286 (2003).
Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041–2046 (2003).
Minamiyama, M. et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 13, 1183–1192 (2004).
Petri, S. et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 22, 40–49 (2006).
Parmigiani, R. B. et al. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc. Natl Acad. Sci. USA 105, 9633–9638 (2008).
Lin, T. et al. Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver. Surgery 141, 784–794 (2007).
Sailhamer, E. A. et al. Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans. Surgery 144, 204–216 (2008).
Alam, H. B. et al. Impact of resuscitation strategies on the acetylation status of cardiac histones in a swine model of hemorrhage. Resuscitation 76, 299–310 (2008).
Li, Y. et al. Cell protective mechanism of valproic acid in lethal hemorrhagic shock. Surgery 144, 217–224 (2008).
Vojinovic, J., Dinarello, C. A., Damjanov, N. & Oldoni, T. Safety and efficacy of oral ITF 2357 in patients with active systemic onset juvenile idopathic arthritis (SOJIA) — results of a phase II open label, international, multicentre clinical trial. Arthritis Rheum. 58, S943 (2008).
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151–1164 (1995).
Fisson, S. et al. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J. Exp. Med. 198, 737–746 (2003).
Chen, W. et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor FOXP3. J. Exp. Med. 198, 1875–1886 (2003).
Liang, S. et al. Conversion of CD4+ CD25- cells into CD4+CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201, 127–137 (2005).
Almeida, A. R., Zaragoza, B. & Freitas, A. A. Competition controls the rate of transition between the peripheral pools of CD4+CD25- and CD4+CD25+ T cells. Int. Immunol. 18, 1607–1613 (2006).
Coombes, J. L. et al. A functionally specialized population of mucosal CD103+ DCs induces FOXP3+ regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757–1764 (2007).
Sun, C. M. et al. Small intestine lamina propria dendritic cells promote de novo generation of FOXP3 T reg cells via retinoic acid. J. Exp. Med. 204, 1775–1785 (2007).
Heinonen, K. M. & Perreault, C. Development and functional properties of thymic and extrathymic T lymphocytes. Crit. Rev. Immunol. 28, 441–466 (2008).
Pasare, C. & Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299, 1033–1036 (2003).
Dominitzki, S. et al. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FOXP3 in naive CD4+CD25 T cells. J. Immunol. 179, 2041–2045 (2007).
Korn, T. et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into FOXP3+ regulatory T cells. Proc. Natl Acad. Sci. USA 105, 18460–18465 (2008).
Shevach, E. M. Mechanisms of FOXP3+ T regulatory cell-mediated suppression. Immunity 30, 636–645 (2009).
Izcue, A., Coombes, J. L. & Powrie, F. Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 27, 313–338 (2009).
Wing, K. et al. CTLA-4 control over FOXP3+ regulatory T cell function. Science 322, 271–275 (2008).
Tao, R., Wang, L., Murphy, K. M., Fraser, C. C. & Hancock, W. W. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J. Immunol. 180, 6649–6655 (2008).
Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257–1265 (2007).
Borsellino, G. et al. Expression of ectonucleotidase CD39 by FOXP3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110, 1225–1232 (2007).
Cobbold, S. P. et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl Acad. Sci. USA 106, 12055–12060 (2009). Fascinating extension of the concept that T regs can act by competing for essential nutrients by moving beyond the tryptophan/IDO concept to use multiple signalling pathways.
Stroud, J. C. et al. Structure of the forkhead domain of FOXP2 bound to DNA. Structure 14, 159–166 (2006). Landmark structure–function modelling of FOXP2–DNA binding that has influenced the view of FOXP3 functions.
Li, B. et al. FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. Int. Immunol. 19, 825–835 (2007). Further biochemical analysis by this group of muticomponent FOXP3 complexes.
Zhou, Z., Song, X., Li, B. & Greene, M. I. FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity. Immunol. Res. 42, 19–28 (2008).
Bettelli, E., Dastrange, M. & Oukka, M. FOXP3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc. Natl Acad. Sci. USA 102, 5138–5143 (2005).
Wu, Y. et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375–387 (2006).
Grant, C. et al. FOXP3 represses retroviral transcription by targeting both NF-kappa B and CREB pathways. PLoS Pathog 2, e33 (2006).
Ono, M. et al. FOXP3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446, 685–689 (2007).
Lee, S. M., Gao, B. & Fang, D. FOXP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1. Blood 111, 3599–3606 (2008).
Li, B. & Greene, M. I. FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 6, 1432–1436 (2007).
Lucas, J. L. et al. Induction of FOXP3+ regulatory T cells with histone deacetylase inhibitors. Cell. Immunol. 257, 97–104 (2009).
Wang, L., Tao, R. & Hancock, W. W. Using histone deacetylase inhibitors to enhance FOXP3+ regulatory T-cell function and induce allograft tolerance. Immunol. Cell Biol. 87, 195–202 (2009).
Koenen, H. J. et al. Human CD25highFOXP3+ regulatory T cells differentiate into IL-17-producing cells. Blood 112, 2340–2352 (2008).
Kinugasa, F. et al. Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transpl. Immunol. 21, 198–202 (2009).
Chung, Y. L., Lee, M. Y., Wang, A. J. & Yao, L. F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8, 707–717 (2003).
Mai, A. et al. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J. Med. Chem. 46, 4826–4829 (2003).
Jones, P. et al. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg Med. Chem. Lett. 18, 3456–3461 (2008).
Estiu, G. et al. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem. 51, 2898–2906 (2008).
Mai, A. et al. New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations. Int. J. Biochem. Cell Biol. 41, 235–247 (2009).
Sengupta, N. & Seto, E. Regulation of histone deacetylase activities. J. Cell Biochem. 93, 57–67 (2004).
Wong, R. H. et al. A role of DNA-PK for the metabolic gene regulation in response to insulin. Cell 136, 1056–1072 (2009).
Wang, L. et al. HDAC7 targeting enhances FOXP3+ Treg function and induces long-term allograft survival. Am. J. Transplant 9, S621 (2009).
Hancock, W. W., Wang, L., de Zoeten, E. F., Bradner, J. E. & Mazitschel, R. HDAC6 is a key new epigenetic target for the enhancement of Treg production and function in vitro and in vivo. Am. J. Transplant 8, S223 (2008).
Bardel, E., Larousserie, F., Charlot-Rabiega, P., Coulomb-L'Hermine, A. & Devergne, O. Human CD4+ CD25+ FOXP3+ regulatory T cells do not constitutively express IL-35. J. Immunol. 181, 6898–6905 (2008).
Shevach, E. M. Mechanisms of FOXP3+ T Regulatory cell-mediated suppression. Immunity 30, 636–645 (2009).
Gallimore, A. M. & Simon, A. K. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 27, 5886–5893 (2008).
Lawson, J. M. et al. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154, 353–359 (2008).
D'Alise, A. M. et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc. Natl Acad. Sci. USA 105, 19857–19862 (2008).
Strevel, E. L., Ing, D. J. & Siu, L. L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J. Clin. Oncol. 25, 3362–3371 (2007).
Carducci, M. A. et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 7, 3047–3055 (2001).
Kelly, W. K. et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9, 3578–3588 (2003).
Ryan, Q. C. et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23, 3912–3922 (2005).
Klimek, V. M. et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 14, 826–832 (2008).
Barnes, P. J. Role of HDAC2 in the Pathophysiology of COPD. Annu. Rev. Physiol. (2008).
Adenuga, D., Yao, H., March, T. H., Seagrave, J. & Rahman, I. Histone deacetylase 2 is phosphorylated, ubiquitinated and degraded by cigarette smoke. Am. J. Respir. Cell. Mol. Biol. 40, 464–473 (2009).
Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207–212 (2009).
Bots, M. & Johnstone, R. W. Rational combinations using HDAC inhibitors. Clin. Cancer Res. 15, 3970–3977 (2009).
Wang, L., Tao, R., Friedlander, J. A. & Hancock, W. W. Tolerance without immunosuppression: Exploiting epigenetic regulation as a new approach to achieving donor-specific allograft tolerance. Am. J. Transplant 8, S203 (2008).
Author information
Authors and Affiliations
Corresponding author
Glossary
- Histone deacetylase
-
(HDAC). Enzyme that catalyses removal of acetyl groups from lysines in histone tails or non-histone proteins; such deacetylation usually decreases gene expression or protein function. Classical HDACs are those which are zinc-dependent and include HDACs 1–11. Sirtuins are a distinctly different family of HDACs (SIRT1–7) that are NAD-dependent and are mainly involved in cell metabolism.
- FOXP3
-
Forkhead or winged helix transcription factor that is expressed primarily in regulatory T cells and controls their functions; its DNA binding and interactions with other proteins are promoted by acetylation and impaired by deacetylation. Mutations in FOXP3 are responsible for life-threatening autoimmunity in patients and experimental animals.
- Regulatory T cell
-
(Treg). These cells express FOXP3 and dampen immune responses mediated by T and B cells. They may also modulate functions of cells of the innate immune system. They function by multiple mechanisms, including direct membrane–membrane effects, the release of soluble products and catabolism of essential amino acids.
- Histone acetyltransferase
-
(HAT). Enzymes that catalyse acetylation of key lysines in histone tails and various non-histone proteins; such acetylation usually promotes gene expression or protein function.
- Aggresome
-
An intracellular inclusion body that stores misfolded intracellular proteins and recruits motor proteins to transport misfolded or aggregated proteins to chaperones and proteasomes for subsequent destruction.
Rights and permissions
About this article
Cite this article
Wang, L., de Zoeten, E., Greene, M. et al. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 8, 969–981 (2009). https://doi.org/10.1038/nrd3031
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3031
This article is cited by
-
Role of the gut microbiome in chronic diseases: a narrative review
European Journal of Clinical Nutrition (2022)
-
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Molecular Cancer (2021)
-
IL-4 inhibits regulatory T cells differentiation by HDAC9-mediated epigenetic regulation
Cell Death & Disease (2021)
-
Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer
Cancer Immunology, Immunotherapy (2021)
-
B cell-intrinsic epigenetic modulation of antibody responses by dietary fiber-derived short-chain fatty acids
Nature Communications (2020)